Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin  by Chan, Yi-Hsin et al.
Listen to this manuscript’s
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 8 , N O . 2 1 , 2 0 1 6
ª 2 0 1 6 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E AM E R I C A N
C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .
I S S N 0 7 3 5 - 1 0 9 7
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 6 . 0 8 . 0 6 3Acute Kidney Injury in
Asians With Atrial Fibrillation
Treated With Dabigatran or Warfarin
Yi-Hsin Chan, MD,a,b Yung-Hsin Yeh, MD,a,b Lai-Chu See, PHD,c,d,e Chun-Li Wang, MD,a,b
Shang-Hung Chang, MD, PHD,a,b Hsin-Fu Lee, MD,a,b Lung-Sheng Wu, MD,a,b Hui-Tzu Tu, MS,c Chi-Tai Kuo, MDa,bABSTRACTFro
Gu
dB
of
Ta
fro
CM
ha
MaBACKGROUND Whether dabigatran is associated with a lower risk of acute kidney injury (AKI) in patients with
nonvalvular atrial ﬁbrillation (NVAF) remains unknown.
OBJECTIVES The authors compared the risk of AKI in Asians with NVAF who were prescribed dabigatran
versus warfarin.
METHODS The authors analyzed patients enrolled in the Taiwan nationwide retrospective cohort study from June 1,
2012, to December 31, 2013. Dabigatran and warfarin were taken by 7,702 and 7,885 NVAF patients without a history of
chronic kidney disease (CKD) and 2,256 and 2,089 NVAF patients with a history of CKD, respectively. A propensity-score
weighted method was used to balance covariates across study groups.
RESULTS A total of 6,762 (88%) and 940 (12%) CKD-free patients and 2,025 (90%) and 231 (10%) CKD patients took
dabigatran 110 mg and 150 mg twice daily, respectively. Dabigatran was associated with a lower risk of AKI than warfarin
for either the CKD-free (hazard ratio [HR]: 0.62; 95% conﬁdence interval [CI]: 0.49 to 0.77; p < 0.001) or CKD
(HR: 0.56; 95% CI: 0.46 to 0.69; p < 0.001) cohort. As the increment in CHA2DS2-VASc score (a risk score based on
congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack,
vascular disease, aged 65 to 74 years, and female sex) increased from 0/1 to 6þ points, the incidence of AKI for the
dabigatran group was relatively stable (1.87% to 2.91% per year for the CKD-free cohort; 7.31% to 13.15% per year for
the CKD cohort) but increased obviously for patients taking warfarin for either CKD-free (2.00% to 6.16% per year) or
CKD cohorts (6.82 to 26.03% per year). The warfarin group had a signiﬁcantly higher annual risk of AKI than the
dabigatran group for those with a high CHA2DS2-VASc score ($4 for the CKD-free cohort and $3 for the CKD cohort).
Subgroup analysis revealed that among dabigatran users, those taking either low-dose or standard-dose dabigatran,
those with a warfarin-naïve or warfarin-experienced history, those with or without diabetes, and those with CHA2DS2-
VASc $4 or HAS-BLED $3 (risk score based on hypertension, abnormal renal and liver function, stroke, prior major
bleeding, labile international normalized ratios, age 65 years or older, drugs or alcohol usage history) all had a lower risk
of AKI than those taking warfarin.
CONCLUSIONS Among Asians with NVAF, dabigatran is associated with a lower risk of AKI than warfarin.
(J Am Coll Cardiol 2016;68:2272–83) © 2016 The Authors. Published by Elsevier on behalf of the American College of
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
AKI = acute kidney injury
ASMD = absolute standardized
mean difference
CHA2DS2-VASc = congestive
heart failure, hypertension, age
75 years or older, diabetes
mellitus, previous stroke/
transient ischemic attack,
vascular disease, age 65 to 74
years, female
CKD = chronic kidney disease
GFR = glomerular ﬁltration
rate
HAS-BLED = hypertension,
abnormal renal and liver
function, stroke, prior major
bleeding, labile INRs, aged 65
years or older, drugs or alcohol
usage history
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2273O ral anticoagulant drugs (OACs), likevitamin K antagonists (e.g., warfarin),have been shown to decrease the risk of
thromboembolic events and all-cause mortality in
patients with atrial ﬁbrillation (AF) (1). OACs can
also increase the risk of hemorrhage caused by coa-
gulopathy. Although warfarin has been commonly
used for more than 60 years, its harmful effects on
renal function (so-called warfarin-related nephropa-
thy [WRN]) have only recently been recognized
(2,3). It is estimated that as many as 20.5% of all
patients taking warfarin have experienced at least
1 episode of WRN during their treatment course,
with most cases occurring within 1 year after the initi-
ation of treatment (3,4). Dabigatran, a competitive
direct thrombin inhibitor, is increasingly used for
the prevention of ischemic stroke and systemic embo-
lism in patients with nonvalvular AF as a safer alter-
native to warfarin with a lower risk of intracranial
hemorrhage and other causes of major bleeding (5).SEE PAGE 2284
ICD-9-CM = International
Classiﬁcation of Diseases-Ninth
Revision-Clinical Modiﬁcation
INR = international normalized
ratio
NHIRD = National Health
Insurance Registry Database
NOAC = non–vitamin K
antagonist oral anticoagulant
OAC = oral anticoagulant
WRN = warfarin-related
ropathyDabigatran is excreted primarily from the kidney;
however, little is known about its effects on kidney
function. In animal models, dabigatran has been
shown to produce acute kidney injury (AKI) and he-
maturia, similar to warfarin (6). Although the inci-
dence of AKI was not signiﬁcantly different between
dabigatran and warfarin in the RE-LY (Randomized
Evaluation of Long-Term Anticoagulation Therapy)
trial, there have been some case reports of AKI occur-
ring with dabigatran use (7,8). Interestingly, the
post hoc analysis of RE-LY indicated that patients
with AF receiving dabigatran exhibited a slower
decline in renal function than those taking warfarin,
and the decline of renal function was ampliﬁed by
previous warfarin use and the presence of diabetes
mellitus (9). The magnitude of AKI risk associated
with dabigatran and warfarin as administered to AF
patients remains unknown in the real-world clinical
setting. The objective of this study was to compare
the risk of AKI associated with dabigatran versus
warfarin among patients with nonvalvular AF.
METHODS
STUDY POPULATION. This was a nationwide retro-
spective cohort study in which all patient data were
obtained from the Taiwan National Health Insurance
Registry Database (NHIRD). The National Health
Insurance program is a mandatory universal health
insurance system in Taiwan, which has contracts with
97% of the hospitals in Taiwan and provides
comprehensive medical care coverage to 99% of the23.74 million Taiwanese. Because the original
NHIRD identiﬁcation number belonging to
each patient is encrypted and de-identiﬁed to
protect their privacy, informed consent was
waived for this study. The claims for each
individual patient could be linked and
continuously followed because of the
consistent data encryption process used. Di-
agnoses were coded according to the Inter-
national Classiﬁcation of Diseases-Ninth
Revision-Clinical Modiﬁcation (ICD-9-CM).
The study protocol was approved by the
Institutional Review Board of Chang Gung
Memorial Hospital, Taiwan.
STUDY DESIGN AND OUTCOME. A cohort
with 2 study groups (dabigatran and warfarin)
was used in this study. A ﬂowchart of the
study cohort enrollment is shown in Figure 1. A
total of 304,252 new AF patients (ICD-9-CM
code 427.31) were identiﬁed from January 1,
1996, to December 31, 2013. Among these
304,252 patients, 89,705 had at least 1 pre-
scription ﬁlled for dabigatran or warfarin after
AF was diagnosed. The approval date for
dabigatran in Taiwan was June 1, 2012. The
index date was deﬁned as the ﬁrst date
of prescribing dabigatran or warfarin after
June 1, 2012. Patients were excluded if
they had pulmonary embolism or deep vein
thrombosis within 6 months before AF diag-
nosis (n ¼ 1,618), received joint replacement or
valvular surgery within 6 months before AF diagnosis
(n ¼ 2,747), had end-stage renal disease before the
index date (n ¼ 9,651), were <30 years of age (n ¼ 223),
had taken dabigatran ﬁrst and then switched to
warfarin (n ¼ 284), or had started taking warfarin
before June 1, 2012, and did not shift to dabigatran
after June 1, 2012 (n ¼ 55,250). In total, 19,932 patients
were eligible for this study. Of these, 15,587 did not
have a history of chronic kidney disease (CKD)
compared with 4,345 who did before the index date.
Patients with CKD history were deﬁned as those who
were diagnosed with ICD-9-CM codes 580 through 589
at least twice at an outpatient clinic or at discharge
(10). Among patients without any history of CKD, 7,702
and 7,885 patients took the ﬁrst dose of dabigatran or
warfarin, respectively, from June 1, 2012, to December
31, 2013, based on each patient’s ﬁnal anticoagulant
status. Among patients with a history of CKD, 2,256
and 2,089 patients took the ﬁrst dose of dabigatran or
warfarin, respectively, during the same time period.
The follow-up period was deﬁned from the index
date until the ﬁrst occurrence of AKI or the end
neph
FIGURE 1 Enrollment of Patients With Nonvalvular AF
New AF patients from 1996-2013
(n=304,252)
Taking dabigatran (D) or
warfarin (W) after AF diagnosed
(n=89,705)
Kidney disease history (-)
June 1, 2012 – Dec. 31, 2013
(n=15,587)
Kidney disease history (+)
June 1, 2012 – Dec. 31, 2013
(n=4,345)
Dabigatran users
(n=7,702)
Warfarin users
(n=7,885)
Dabigatran users
(n=2,256)
Warfarin users
(n=2,089)
Followed from the index date* until the occurrence of first event of acute kidney injury or Dec.
31, 2013, whichever came first.
Exclusion if:
Patient was diagnosed with
pulmonary embolism or deep
vein thrombosis within 6
months before AF diagnosed
(n=1,618)
Patients received joint
replacement or valvular
surgery within 6 months before
AF diagnosed (n=2,747)
Patients were diagnosed with
end-stage renal disease
before index date (n=9,651)
Patients <30 years of age
(n=223)
D     W users (n=284)
Patients started W before June
1, 2012 and didn’t shift to D
thereafter (n=55,250)
-
-
-
-
-
-
From June 1, 2012, to December 31, 2013, this study evaluated a total of 7,702 dabigatran versus 7,885 warfarin users who had nonvalvular
atrial ﬁbrillation (AF) and no previous history of chronic kidney disease (CKD). Another study cohort of 2,256 dabigatran and 2,089 warfarin
users with previous history of CKD was also enrolled during the same study period. *The index date was deﬁned as the ﬁrst date of prescribing
dabigatran or warfarin after June 1, 2012 for each group. D ¼ dabigatran; W ¼ warfarin.
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whichever came ﬁrst. The outcome of AKI was
deﬁned as those who received a diagnosis coded as
ICD-9-CM 580.X, 584.X, or 586 during hospitaliza-
tion or during at least 1 outpatient visit. The vali-
dation of ICD-9-CM codes for identifying AKI was
performed previously, and the positive predictive
value of AKI was 0.96 compared with the clinical
diagnosis of AKI based on the Acute Kidney Injury
Network criteria (11,12). The deﬁnition of AKI usingthe Acute Kidney Injury Network criteria was an
absolute increase in serum creatinine of $0.3 mg/dl,
a percentage increase in serum creatinine of $50%,
or a reduction in urine output (documented oliguria
of <0.5 ml/kg/h for more than 6 h) within 48 h (12).
Other studies have also validated the diagnostic
accuracy of AKI records in the NHIRD (13,14).
ICD-9-CM codes used for the study outcomes and
other baseline covariates are summarized in Online
Table 1.
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2275VALIDATION. We also validated the ICD-9-CM codes
for identifying AKI by analyzing the medical records
of 372 consecutive AF patients in the inpatient claims
database of Chang Gung Memorial Hospital, Linkou,
the largest medical center in Taiwan, between
January 2010 and December 2015. Clinical diagnosis
of AKI was determined according to the Acute Kidney
Injury Network criteria (12). There were 130 conﬁrmed
cases of AKI during the hospital course, and 119 could
be identiﬁed by an ICD-9-CM code indicating AKI
(580.X, 584.X, and 586) in the discharge claims. The
sensitivity, speciﬁcity, positive predictive value, and
negative predictive value of ICD-9-CM code to indi-
cate AKI versus a clinical diagnosis of AKI based on
the Acute Kidney Injury Network criteria were 0.92,
1.00, 1.00, and 0.96, respectively. The following
equations were used: sensitivity ¼ [TP / (TP þ FN)],
speciﬁcity ¼ [TN / (TN þ FP)], positive predictive
value ¼ [TP / (TP þ FP)], and negative predictive
value ¼ [TN / (TN þ FN)], where TP is true positive,
TN is true negative, FP is false positive, and FN is
false negative.
COVARIATES. Risk factors for kidney injury, inclu-
ding age, comorbidities, previous bleeding history,
and medication history, such as use of nonsteroidal
anti-inﬂammatory drugs, angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers,
aminoglycoside, and steroids at baseline, were refer-
enced to any claim record with the previously
mentioned diagnoses or medication codes before the
index date. A speciﬁc medication history was conﬁned
to at least 1 prescription within 3months preceding the
index date. A bleeding history was conﬁned to events
within 6 months preceding the index date (15). The
CHA2DS2-VASc score was calculated based on the
summation of the following risk factors: 2 points for
age 75 years or older or previous stroke/transient
ischemic attack and 1 point each for congestive heart
failure, hypertension, diabetes mellitus, vascular dis-
ease, age 65 to 74 years, and female sex (15). The HAS-
BLED score was calculated according to the summa-
tion of the following risk factors (1 point for each risk
factor if present): hypertension, abnormal renal and
liver function, stroke, prior major bleeding, labile in-
ternational normalized ratios (INRs), age 65 years or
older, and history of drug or alcohol use (15).
STATISTICAL ANALYSIS. The risk of AKI for dabiga-
tran versus warfarin (reference) was obtained using
incidence rate and survival analysis (Kaplan-Meier
method and log-rank test for univariate analysis, and
Cox proportional hazards regression for multivariate
analysis). Incidence rates were calculated using the
total number of study outcomes during the follow-upperiod divided by person-years at risk. The pro-
pensity score method, which simulates the random-
ized allocation in a clinical trial for observational
cohort data, was used to examine the effects of
dabigatran and warfarin on AKI.
The propensity score is the predicted probability of
treatment conditioned on selected covariates using
logistic regression. In this study, all baseline charac-
teristics in Tables 1 and 2 were included in the logistic
regression to obtain the propensity score, except for
CHA2DS2-VASc and HAS-BLED scores, because these
latter 2 variables are a combination of some of the
comorbidities in Tables 1 and 2. The inverse proba-
bility of treatment weights of propensity scores was
used to balance covariates between dabigatran users
and warfarin users with regard to time-to-event
analyses (Cox proportional hazards model, log-rank
test, and incidence rate). The balance of covariates
at baseline between dabigatran users and warfarin
users was assessed with the absolute standardized
mean difference (ASMD) rather than statistical
testing, because balance is a property of the sample
and not of an underlying population. ASMD #0.1
indicates a negligible difference in potential con-
founders between the dabigatran and warfarin groups
(16). Subgroup analysis was performed to determine
whether the risk of AKI in the dabigatran group
compared with the warfarin group was similar in
subgroups. Note that propensity score was reobtained
for each subgroup analysis to allow covariate balance
in the 2 user groups. Statistical signiﬁcance was
deﬁned as a p < 0.05. All statistical analyses were
performed with SAS version 9.4 (SAS Institute Inc.,
Cary, North Carolina).
RESULTS
A total of 7,702 and 7,885 consecutive patients
without a previous history of kidney disease who were
taking dabigatran and warfarin, respectively, between
June 1, 2012 and December 31, 2013, were eligible. The
median follow-up period was 0.69 years for dabigatran
users and 0.79 years for warfarin users. Before pro-
pensity score weighting, the dabigatran group was
older, had higher CHA2DS2-VASc and HAS-BLED
scores, and had a higher proportion of comorbidities
than the warfarin group (Table 1). After propensity
score weighting, the dabigatran and warfarin groups
were well balanced for most characteristics
(ASMD<0.1) (Table 1). For the CKD cohort, themedium
follow-up period was 0.69 years for dabigatran users
(n¼ 2,256) and 0.71 years for warfarin users (n¼ 2,089).
Similar to the CKD-free cohort, the dabigatran
group was older and had higher CHA2DS2-VASc and
TABLE 1 Baseline Characteristics of Patients With Nonvalvular Atrial Fibrillation Without Kidney Disease History Taking Dabigatran and
Warfarin, Before and After Propensity Score Weighting
Propensity Score Weighting
Before After
Dabigatran
(n ¼ 7,702)
Warfarin
(n ¼ 7,885) ASMD
Dabigatran
(n ¼ 7,702)
Warfarin
(n ¼ 7,885) ASMD
Age, yrs 75  10 70  12 0.4059 75  10 75  10 0.0321
<65 14 33 14 13
65–74 30 27 30 29
75–84 42 29 42 43
>85 14 12 14 15
Male 57 55 0.0447 57 56 0.0133
CHA2DS2-VASc 4.02  1.59 3.20  1.79 0.4810 4.02  1.59 4.06  1.73 0.0283
HAS-BLED 2.87  0.99 2.46  1.16 0.3779 2.87  0.99 2.94  1.07 0.0687
Chronic liver disease 24 19 0.1317 24 24 0.0019
Congestive heart failure 14 13 0.0250 14 14 0.0034
Hypertension 85 73 0.3002 85 85 0.0136
Hyperlipidemia 48 37 0.2156 48 48 0.0062
Diabetes mellitus 38 31 0.1406 38 38 0.0074
Previous stroke 33 20 0.3005 33 33 0.0094
Previous TIA 5 2 0.1547 5 5 0.0139
Myocardial infarction 3 3 0.0026 3 3 0.0038
History of bleeding 1 1 0.0160 1 1 0.0207
Use of NSAIDs 25 28 0.0841 25 26 0.0242
Use of antiplatelet agents 47 61 0.2901 47 53 0.1134
Use of aminoglycoside 2 4 0.1161 2 2 0.0109
Use of ACEI/ARB 63 60 0.0579 63 62 0.0039
Use of steroids 5 9 0.1608 5 6 0.0173
PCI 7 5 0.0608 7 7 0.0212
CABG 1 1 0.0355 1 1 0.0080
Values are mean  SD or %.
ACEI ¼ angiotensin-converting-enzyme inhibitor; ARB ¼ angiotensin II receptor antagonists; ASMD ¼ absolute standardized mean difference; CABG ¼ coronary artery bypass
graft; CHA2DS2-VASc¼ congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65 to 74
years, female (15); HAS-BLED ¼ hypertension, abnormal renal or liver function, stroke, bleeding history, labile international normalized ratio, age 65 years or older, and
antiplatelet drug or alcohol use (15) (labile international normalized ratio could not be determined from claims and was excluded from our scoring); PCI ¼ percutaneous
coronary intervention; NSAIDs ¼ nonsteroidal anti-inﬂammatory drugs; TIA ¼ transient ischemic attack.
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pensity score weighting (Table 2).
In the CKD-free cohort, the incidence rate for AKI
was 2.17 (95% CI: 1.78 to 2.56) and 3.47 (95% CI: 2.99
to 3.95) per 100 person-years for the dabigatran and
warfarin groups, respectively. In the CKD cohort, the
incidence rate for AKI was 9.28 (95% CI: 7.76 to 10.79)
and 16.21 (95% CI: 14.22 to 18.19) per 100 person-years
for the dabigatran and warfarin groups, respectively.
In the CKD-free cohort, there were 71% and 68%
inpatient diagnoses of AKI in the dabigatran and
warfarin groups, respectively. In the CKD cohort,
there were 53% and 47% inpatient diagnoses of AKI in
the dabigatran and warfarin groups, respectively. The
mortality rate was 3.09% per year (95% CI: 2.62% to
3.56% per year) versus 5.92% per year (95% CI: 5.30%
to 6.54% per year) in the CKD-free cohort and 5.52%
per year (95% CI: 4.37% to 6.66% per year) versus
12.52% per year (95% CI: 10.84% to 14.20% per year)in the CKD cohort, respectively, in the dabigatran and
warfarin groups. The incidence of need for renal
replacement therapy was 0.00% per year (95% CI:
0.00% to 0.00% per year) versus 0.03% per year
(95% CI: 0.00% to 0.12% per year) in the CKD-free
cohort and 0.37% per year (95% CI: 0.14% to 0.81%
per year) versus 1.43% per year (95% CI: 0.86% to
2.00% per year) in the CKD cohort, respectively, for
the dabigatran and warfarin groups. Early separation
of cumulative event curves for AKI, renal replace-
ment therapy, and mortality after propensity score
weighting in the 2 study groups were noted for both
the CKD-free and CKD cohorts (Central Illustration,
Online Figures 1 and 2). Dabigatran was associated
with a signiﬁcantly lower risk of AKI than warfarin in
both the CKD-free and CKD cohorts (hazard ratio
[HR]: 0.62; 95% CI: 0.49 to 0.77; p < 0.001 for the
CKD-free cohort and HR: 0.56; 95% CI: 0.46 to 0.69;
p < 0.001 for the CKD cohort, respectively).
TABLE 2 Baseline Characteristics of Patients With Nonvalvular AF With Kidney Disease History Taking Dabigatran and Warfarin, Before
and After Propensity Score Weighting
Propensity Score Weighting
Before After
Dabigatran
(n ¼ 2,256)
Warfarin
(n ¼ 2,089) ASMD
Dabigatran
(n ¼ 2,256)
Warfarin
(n ¼ 2,089) ASMD
Age, yrs 77  9 75  10 0.1839 77  9 77  9 0.0191
<65 7 16 7 7
65-74 26 25 26 26
75-84 48 39 48 48
>85 19 20 19 19
Male 62 59 0.0690 62 62 0.0057
CHA2DS2-VASc score 4.52  1.51 4.17  1.64 0.2265 4.52  1.51 4.50  1.63 0.0126
HAS-BLED score 4.24  0.93 4.11  1.00 0.1307 4.24  0.93 4.28  1.04 0.0456
Chronic liver disease 41 38 0.0672 41 41 0.0075
Congestive heart failure 21 24 0.0679 21 21 0.0011
Hypertension 94 92 0.0695 94 94 0.0060
Hyperlipidemia 66 61 0.0994 66 66 0.0070
Diabetes mellitus 54 53 0.0317 54 54 0.0059
Previous stroke 33 23 0.2341 33 32 0.0278
Previous TIA 7 4 0.1225 7 7 0.0058
Myocardial infarction 4 5 0.0435 4 4 0.0139
History of bleeding 1 1 0.0091 1 2 0.0271
Use of NSAIDs 30 33 0.0503 30 32 0.0334
Use of antiplatelet agents 49 64 0.3191 49 52 0.0718
Use of aminoglycoside 3 4 0.0935 3 3 0.0084
Use of ACEI/ARB 68 67 0.0203 68 68 0.0045
Use of steroids 7 12 0.1798 7 7 0.0112
PCI 10 9 0.0158 10 10 0.0027
CABG 1 2 0.0795 1 1 0.0059
Values are mean  SD or %.
Abbreviations as in Table 1.
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warfarin group increased obviously with incremental
CHA2DS2-VASc score for both the CKD-free and CKD
cohorts, but the annual incidence of AKI for the
dabigatran group was consistent irrespective of the
CHA2DS2-VASc score after propensity score weight-
ing. The annual risk of AKI for the warfarin group
increased from 2.00% (95% CI: 1.13% to 2.86%) to
6.16% (95% CI: 4.33% to 7.99%) and from 6.82%
(95% CI: 2.39% to 15.25%) to 26.03% (95% CI: 20.13%
to 31.93%) for the CKD-free and CKD cohorts,
respectively, whereas the CHA2DS2-VASc score
increased from 0/1 to $6 points. It was noted that the
warfarin group had a signiﬁcantly higher annual risk
of AKI than the dabigatran group for those with high
CHA2DS2-VASc scores (Figure 2).
Subgroup analysis was performed to determine
whether the dabigatran group had a lower risk of AKI
than the warfarin group. In the CKD-free cohort, a total
of 6,762 (88%) and 940 (12%) patients were taking
dabigatran 110mg and 150mg twice daily, respectively.
There were 4,192 patients (54%) with previouswarfarin experience among the dabigatran group.
Among the dabigatran users, those taking low or
standard doses, with or without previous treatment
with warfarin, older or younger than 75 years of age,
and with or without diabetes all had a lower risk of AKI
than those taking warfarin. In contrast to patients with
low CHA2DS2-VASc (<4) or HAS-BLED (<3) scores,
dabigatran userswith high CHA2DS2-VASc ($4) orHAS-
BLED ($3) scores had a lower risk of AKI than with
warfarin (Figure 3). For the CKD cohort, there were
2,025 (90%) and 231 (10%) patients taking dabigatran
110 mg and 150 mg twice daily, respectively. Likewise,
the results indicated that dabigatran was associated
with a lower risk of AKI in most subgroups (Figure 4).
A Cox model was performed without propensity
score weighting to identify the independent risk fac-
tors for new-onset AKI for those patients taking OACs.
Among CKD-free patients taking OACs, age (HR: 1.03;
95% CI: 1.02 to 1.04; p < 0.0001), use of angiotensin-
converting enzyme inhibitors/angiotensin receptor
blockers (HR: 1.37; 95% CI: 1.07 to 1.75; p ¼ 0.0112), use
of steroids (HR: 1.55; 95% CI: 1.10 to 2.17; p ¼ 0.0114),
CENTRAL ILLUSTRATION AKI in Patients With Nonvalvular AF Treated With Dabigatran or Warfarin: Cumulative
Probability After PSW
Chan, Y.-H. et al. J Am Coll Cardiol. 2016;68(21):2272–83.
Dabigatran users (solid line) had a signiﬁcantly lower risk of acute kidney injury (AKI) than warfarin users (dashed line) after propensity score weighting (PSW) in both
the chronic kidney disease (CKD)–free (A) and CKD (B) cohorts. AF ¼ atrial ﬁbrillation.
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2278and presence of congestive heart failure (HR: 1.91;
95% CI: 1.47 to 2.48; p<0.0001) were independent risk
factors for new-onset AKI. It was noted that dabigatran
was still associated with a lower risk of AKI than with
warfarin after multivariate adjustment (HR: 0.61;
95% CI: 0.49 to 0.77; p < 0.0001) (Online Table 2). For
the CKD cohort, age (HR: 1.02; 95% CI: 1.01 to 1.03;
p¼ 0.0002), congestive heart failure (HR: 1.90; 95% CI:
1.54 to 2.34; p < 0.0001), diabetes (HR: 1.23; 95% CI:
1.01 to 1.50; p ¼ 0.0442), use of dabigatran versus
warfarin (HR: 0.55; 95% CI: 0.45 to 0.68; p < 0.0001),
and steroid use (HR: 1.88; 95% CI: 1.44 to 2.45;
p < 0.0001) were independent determinants of
new-onset AKI (Online Table 3).
DISCUSSION
This is the ﬁrst and largest population-based study to
investigate the risk of AKI from OACs with a speciﬁc
focus on Asians with nonvalvular AF taking dabigatran
or warfarin during the same period. Our study showed
that dabigatran was associated with a lower risk of AKIthan warfarin, whether or not patients had any prior
kidney disease. Patients who took warfarin had an
increased risk of AKI as the CHA2DS2-VASc score
increased in both the CKD-free and CKD cohorts. By
contrast, the annual incidence of AKI for dabigatran
users remained stable despite the increment in
CHA2DS2-VASc score. It was noted that the warfarin
group had a signiﬁcantly higher annual risk of AKI than
the dabigatran group for those patients with high
CHA2DS2-VASc scores ($4 for CKD-free cohort and $3
for CKD cohort). Subgroup analysis indicated that
dabigatran users (either low dose or standard dose and
with or without a previous history of taking warfarin)
had a lower risk of AKI than warfarin users.
WRN is a common but underdiagnosed complica-
tion related to treatment with anticoagulant drugs
that is associated with increased mortality and renal
morbidity (3,4). The mechanisms underlying WRN are
complicated and multifactorial, but supratherapeutic
doses of warfarin with an INR >3.0 can result in
glomerular hemorrhage and consequent tubular
injury caused by obstructive tubular red blood cell
FIGURE 2 Annual Risk of Acute Kidney Injury for Patients With Nonvalvular Atrial
Fibrillation Who Were Treated With Dabigatran or Warfarin for Different
CHA2DS2-VASc Scores After Propensity Score Weighting
*
*
*
*
*
*
7
6
5
4
3
2
1
0
0 / 1 2 3 4 5 6+
An
nu
al
 R
isk
 (%
)
CHA2DS2-VASc
0 / 1 2 3 4 5 6+
CHA2DS2-VASc
CKD history: (-)
CKD history: (+)
Dabigatran Warfarin
30
25
20
15
10
5
0
An
nu
al
 R
isk
 (%
)
A
B
Dabigatran users had a signiﬁcantly lower annual risk of acute kidney injury than warfarin
users with CHA2DS2-VASc score $4 for the chronic kidney disease (CKD)–free cohort (A)
and CHA2DS2-VASc score $3 for the CKD cohort (B). CHA2DS2-VASc score ¼ congestive
heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/
transient ischemic attack, vascular disease, age 65 to 74 years, female (15). *p < 0.05.
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2279casts and heme-induced free radical injury (2,17).
Warfarin also facilitates renal vascular calciﬁcation
and the consequent decline in renal function via in-
hibition of the activation of matrix G1a protein and
growth arrest–speciﬁc gene 6 (18–20). Furthermore,
warfarin use has been correlated to other rare
renal complications, including allergic interstitial
nephritis, spontaneous atheromatous embolism, and
renal pelvis/ureteral hematomas (21,22).
Dabigatran and other non–vitamin K antagonist
oral anticoagulant drugs (NOACs) have a predictable
dose-response effect and a lower risk of major
bleeding events than with warfarin in AF patients.
However, the question of the potential renal toxicity
from NOACs remains unanswered. A few case reports
describing dabigatran-related AKI have been reported
(7,8). Ryan et al. (6) recently studied the effects of
dabigatran on renal function in the 5/6 nephrectomy
rat model with CKD. They demonstrated that dabi-
gatran resulted in a dose-dependent increase in
serum creatinine and hematuria in both control and
CKD rats (6). It was noted that the histological ﬁnd-
ings in CKD rats treated with dabigatran were similar
to those found in rats with WRN, involving acute
tubular injury with red blood cell casts in the tubules.
Furthermore, kidney injury was also seen in the
control rats treated with dabigatran. Of note, both
CKD and control rats took high doses of dabigatran,
and thus, their results might not be directly appli-
cable to humans. Ware et al. (23) also reported that
both dabigatran and warfarin increased systolic blood
pressure in a dose-dependent manner in their CKD rat
models, and such increases in blood pressure could
indirectly cause long-term kidney injury. A recent
meta-analysis indicated that the risk of renal failure
from the use of NOACs (dabigatran, apixaban, or
rivaroxaban) was similar to that with traditional
anticoagulant drugs such as warfarin or low-
molecular-weight heparin (24); however, it was
noted that rivaroxaban was associated with an
increased risk of creatinine elevation in the
J-ROCKET and RECORD 1-2 trials (25–27). Neverthe-
less, regular monitoring of renal function is important
to avoid prescribing dabigatran or other NOACs at
inappropriately high doses, especially when renal
function has deteriorated, which can occur in AF pa-
tients with multiple well-known risk factors inde-
pendent of NOAC administration.
Several things might explain why dabigatran
conferred a lower risk of AKI than warfarin in our
Asian cohort. The RE-LY subgroup analysis indicated
that dabigatran, at either low dose or standard dose,
was associated with a lower risk of major bleeding
events in Asian patients, and a major bleeding eventis a common cause of acute renal failure (28,29). Our
recent study of a large nationwide Asian cohort with
nonvalvular AF also indicated that dabigatran was
associated with a reduced risk of ischemic stroke,
intracranial hemorrhage, and all hospitalized major
bleeding, whereas it did not increase the risk of major
gastrointestinal bleeding compared with warfarin
over the same time period (15). The reduced number
of thromboembolic events (e.g., renal infarction) and
FIGURE 3 Forest Plot of Hazard Ratio of Acute Kidney Injury for Patients With Nonvalvular Atrial Fibrillation Without Chronic Kidney Disease History
Taking Dabigatran Versus Warfarin After Propensity Score Weighting
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Dabigatran users taking either low or standard dose and with or without warfarin experience and a high CHA2DS2-VASc ($4) or HAS-BLED ($3) score had a
lower risk of acute kidney injury thanwithwarfarin. ACEI¼ angiotensin-converting enzyme inhibitor; ARB¼ angiotensin II receptor antagonist; CI¼ conﬁdence
interval; HAS-BLED¼ hypertension, abnormal renal or liver function, stroke, bleeding history, labile international normalized ratio, age 65 years or older, and
antiplatelet drug or alcohol use (15) (labile international normalized ratio could not be determined from claims and was excluded from our scoring); HR ¼
hazard ratio; NSAIDs ¼ nonsteroidal anti-inﬂammatory drugs; PYs ¼ person years; TIA ¼ transient ischemic attack; other abbreviations as in Figures 1 and 2.
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2280major bleeding events for dabigatran versus warfarin
might thus contribute to a lower risk of AKI. In
addition, the post hoc analysis from the RE-LY trial
indicated that warfarin was associated with a greater
decline in glomerular ﬁltration rate (GFR) than either
low-dose or standard-dose dabigatran (9). Of note,patients outside the therapeutic range of INR control
(mainly above the target range) and those dabigatran
users with previous warfarin experience had a more
obvious decline in GFR than with warfarin. In addi-
tion, patients with diabetes or older patients had
a more obvious decline in GFR. The authors
FIGURE 4 Forest Plot of Hazard Ratio of Acute Kidney Injury for Patients With Nonvalvular Atrial Fibrillation With Chronic Kidney Disease History
Taking Dabigatran Versus Warfarin After Propensity Score Weighting
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Dabigatran use was associated with a lower risk of acute kidney injury than warfarin use in most subgroups. Abbreviations as in Figure 3.
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2281hypothesized that calciﬁcation of renal arteries,
vascular inﬂammation, and increased plaque load
mediated by the inhibition of vitamin K by warfarin
explained the greater decline in GFR than with dabi-
gatran, which was ampliﬁed by several atheroscle-
rotic factors, including diabetes and old age. Our
results indicated that patients taking warfarin were at
an increased risk of AKI compared with those with
higher CHA2DS2-VASc score, which also supports thenotion that warfarin-related acute renal injury was
precipitated by multiple risk factors related to
atherosclerosis. Finally, it was noted that physicians
tended to prescribe the 110 mg dose (n ¼ 6,762; 88%)
of dabigatran in our Asian population, possibly
because of the smaller body size and greater number
of comorbidities within our Asian cohort (15). If dose-
dependent dabigatran-related nephropathy exists, as
demonstrated by Ryan et al. (6), then a lower dose of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In a
large Asian cohort with or without chronic kidney
disease, dabigatran was associated with a lower risk of
acute kidney injury than warfarin, particularly among
those with higher CHA2DS2-VASc stroke risk scores.
TRANSLATIONAL OUTLOOK: Long-term pro-
spective studies are necessary to assess the risks of
acute kidney injury during anticoagulation with other
target-speciﬁc oral anticoagulant drugs (e.g., rivar-
oxaban, apixaban, and edoxaban).
Chan et al. J A C C V O L . 6 8 , N O . 2 1 , 2 0 1 6
Acute Kidney Injury and Oral Anticoagulants N O V E M B E R 2 9 , 2 0 1 6 : 2 2 7 2 – 8 3
2282dabigatran might result in less kidney damage than
with warfarin. Prospective validation of our results in
a future study is warranted.
STUDY LIMITATIONS. First, the NHIRD does not
contain important laboratory data, including serum
hemoglobin, renal and liver function, and INR for
analysis, which is a common limitation of most health
insurance databases around the world. The favorable
renal outcomes of patients taking dabigatran might
have been attributable in part to a higher baseline
GFR due to a selection bias. However, it is unrea-
sonable to assume those dabigatran users who are
older and have a higher prevalence of hypertension,
diabetes, dyslipidemia, and other comorbidities
(Tables 1 and 2) would have a higher baseline GFR
than the warfarin group. Second, the deﬁnition of AKI
was based on the ICD-9-CM coding indicating acute
kidney disease, which depends completely on each
physician’s choice in clinical practice. Although the
coding indicating AKI in the NHIRD had been vali-
dated previously (11,13,14), heterogeneous contami-
nation of the AKI population cannot be excluded. In
addition, coding errors for other comorbidities regis-
tered by each physician’s choice of treatment
constitute a limitation in the Taiwan NHIRD. Third,
the dabigatran group had signiﬁcantly more comor-
bidities than the warfarin group. Hence, we used a
propensity score model with several variables to
balance the comorbidities of the 2 cohorts and still
obtained a positive result both before and after
weighting. However, residual confounding by
unmeasured factors cannot be excluded. Fourth, the
National Health Insurance program in Taiwan
restricts dabigatran claims to 1) AF patients with a
history of ischemic stroke, transient ischemic attack,
or symptomatic heart failure; 2) AF patients >65 years
of age with at least 1 risk factor, including hyperten-
sion, diabetes, or coronary artery disease; or 3) AF
patients >75 years of age. Therefore, the baseline
diagnostic codes were not totally blinded with respectto the use of a speciﬁc anticoagulant drug. Finally,
the follow-up period for dabigatran administration
was short in our study because the 2014 NHIRD was
unavailable. Although signiﬁcant divergence exists
for AKI risk between dabigatran and warfarin users
during the early phase of treatment, it is unclear
whether the beneﬁcial effect of dabigatran persists
during long-term follow-up.
CONCLUSIONS
Dabigatran was associated with a reduced risk of AKI
compared with warfarin in a large Asian cohort either
with or without a history of kidney disease. Either
low-dose or standard-dose dabigatran might be a
safer alternative to warfarin in patients with non-
valvular AF to avoid the risk of anticoagulant-related
AKI. Of note, warfarin conveyed a signiﬁcantly higher
risk of AKI than dabigatran for those patients with
high CHA2DS2-VASc scores.
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